CAPR (Capricor Therapeutics) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $20.59
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

CAPR
37GF Score
Capricor Therapeutics Inc CAPR
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $20.59 is trading 322.8% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • Cash Payments:
  • GF Value™: $4.87 vs. price of $20.59 (322.8% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.59
Price
$4.87
GF Value